The chemical class of CALCA activators plays a pivotal role in unraveling the intricate mechanisms governing neuropeptide synthesis and release. Forskolin, a potent activator, stimulates CALCA by increasing intracellular cAMP levels. This activates protein kinase A (PKA), leading to the phosphorylation and activation of CALCA. Consequently, CALCA facilitates the synthesis and release of neuropeptides, modulating neuroendocrine functions and contributing to pain perception. Bay K 8644 enhances CALCA activity by promoting the function of CaV1.2 calcium channels. This elevation in intracellular calcium levels stimulates CALCA expression and release, influencing neuroendocrine signaling and pain perception. PMA, a PKC activator, phosphorylates CALCA, promoting its secretion and impacting neuropeptide-mediated functions, including inflammation and nociception. 8-Bromo-cAMP mimics the effects of cAMP, stimulating PKA-mediated CALCA phosphorylation and enhancing neuropeptide release.
GW9508, by acting as a selective GPR40 agonist, triggers intracellular calcium influx, leading to increased CALCA expression and release. Anemonin and Baicalein activate CALCA by inhibiting NF-κB, relieving its suppressive effects on CALCA gene expression. These compounds enhance CALCA synthesis and release, modulating neuroinflammatory responses and pain perception. CGS 21680, a ligand for adenosine A2A receptors, activates CALCA through cAMP-dependent signaling, impacting neuroendocrine functions. PACAP and Calcimycin contribute to CALCA activation by binding to PAC1 receptors and inducing intracellular calcium influx, respectively. These activators stimulate CALCA expression and release, influencing neuropeptide-mediated functions and pain perception. Apigenin, through NF-κB inhibition, enhances CALCA synthesis and release, modulating neuroinflammatory signaling. In essence, the CALCA activators, with their diverse mechanisms of action, offer a nuanced understanding of neuropeptide modulation. By dissecting the intricacies of CALCA activation, these compounds provide valuable insights into the regulation of neuroendocrine functions and pain perception, laying the groundwork for further exploration in the realm of neuropeptide-mediated cellular responses.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates CALCA by stimulating adenylyl cyclase, elevating intracellular cAMP levels. Increased cAMP activates protein kinase A (PKA), which phosphorylates and activates CALCA, promoting peptide synthesis and release. | ||||||
(±)-Bay K 8644 | 71145-03-4 | sc-203324 sc-203324A sc-203324B | 1 mg 5 mg 50 mg | $84.00 $196.00 $817.00 | ||
Bay K 8644 activates CALCA by enhancing CaV1.2 calcium channel activity. Increased intracellular calcium levels stimulate CALCA expression and release, modulating neuroendocrine functions and pain perception. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates CALCA through PKC activation. PKC phosphorylates CALCA, promoting its secretion and modulating neuropeptide-mediated functions, including pain perception and inflammation. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $126.00 $328.00 | 30 | |
8-Bromo-cAMP activates CALCA by mimicking the effects of cAMP, stimulating PKA-mediated CALCA phosphorylation. This activation enhances neuropeptide release, impacting neuroendocrine signaling and nociception. | ||||||
GW 9508 | 885101-89-3 | sc-203069 | 10 mg | $128.00 | ||
GW9508 activates CALCA by acting as a selective agonist for GPR40, leading to intracellular calcium influx. Increased calcium levels stimulate CALCA expression and release, influencing neuroendocrine and inflammatory responses. | ||||||
CGS 21680 Hydrochloride | 124431-80-7 | sc-211062 sc-211062A | 10 mg 50 mg | $292.00 $1044.00 | 7 | |
CGS 21680 activates CALCA by binding to adenosine A2A receptors, triggering cAMP-dependent signaling. Elevated cAMP levels activate PKA, leading to CALCA phosphorylation and increased neuropeptide release, affecting neuroendocrine functions. | ||||||
Apigenin | 520-36-5 | sc-3529 sc-3529A sc-3529B sc-3529C sc-3529D sc-3529E sc-3529F | 5 mg 100 mg 1 g 5 g 25 g 100 g 1 kg | $33.00 $214.00 $734.00 $1151.00 $2348.00 $3127.00 $5208.00 | 22 | |
Apigenin activates CALCA by inhibiting NF-κB, relieving its suppression on CALCA gene expression. This activation enhances CALCA synthesis and release, modulating neuroinflammatory responses and pain perception. | ||||||
Baicalein | 491-67-8 | sc-200494 sc-200494A sc-200494B sc-200494C | 10 mg 100 mg 500 mg 1 g | $32.00 $42.00 $162.00 $292.00 | 12 | |
Baicalein activates CALCA by inhibiting NF-κB, attenuating its suppressive effects on CALCA gene expression. This activation enhances CALCA synthesis and release, impacting neuroinflammatory signaling and nociception. | ||||||
Adenosine 3′,5′-cyclic Monophosphate, N6-Benzoyl-, Sodium Salt | 30275-80-0 | sc-300167 | 10 µmol | $324.00 | 1 | |
6-Bnz-cAMP activates CALCA by mimicking the effects of cAMP, stimulating PKA-mediated CALCA phosphorylation. This activation enhances neuropeptide release, influencing neuroendocrine functions and nociception. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
Calcimycin activates CALCA by inducing intracellular calcium influx. Increased calcium levels stimulate CALCA expression and release, modulating neuroendocrine functions and pain perception. | ||||||